GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (FRA:3T2) » Definitions » Cyclically Adjusted Price-to-FCF

T2 Biosystems (FRA:3T2) Cyclically Adjusted Price-to-FCF : (As of Sep. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


T2 Biosystems Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for T2 Biosystems's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Cyclically Adjusted Price-to-FCF Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

T2 Biosystems Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of T2 Biosystems's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, T2 Biosystems's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's Cyclically Adjusted Price-to-FCF falls into.



T2 Biosystems Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

T2 Biosystems's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, T2 Biosystems's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.609/132.5538*132.5538
=-0.609

Current CPI (Jun. 2024) = 132.5538.

T2 Biosystems Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -50.306 100.428 -66.398
201412 -38.640 99.070 -51.700
201503 -40.701 99.621 -54.156
201506 -55.837 100.684 -73.511
201509 -57.798 100.392 -76.315
201512 -46.089 99.792 -61.220
201603 -51.930 100.470 -68.513
201606 -51.148 101.688 -66.673
201609 -45.536 101.861 -59.257
201612 -34.787 101.863 -45.268
201703 -43.997 102.862 -56.697
201706 -37.964 103.349 -48.692
201709 -31.516 104.136 -40.117
201712 -25.777 104.011 -32.851
201803 -26.578 105.290 -33.460
201806 -20.467 106.317 -25.518
201809 -20.438 106.507 -25.436
201812 -18.599 105.998 -23.259
201903 -26.093 107.251 -32.249
201906 -18.117 108.070 -22.222
201909 -27.652 108.329 -33.835
201912 -19.061 108.420 -23.304
202003 -19.535 108.902 -23.778
202006 -10.002 108.767 -12.189
202009 -3.752 109.815 -4.529
202012 -5.067 109.897 -6.112
202103 -5.047 111.754 -5.986
202106 -5.735 114.631 -6.632
202109 -4.962 115.734 -5.683
202112 -5.340 117.630 -6.018
202203 -386.412 121.301 -422.259
202206 -273.086 125.017 -289.550
202209 -269.817 125.227 -285.605
202212 -132.230 125.222 -139.972
202303 -89.691 127.348 -93.358
202306 -14.169 128.729 -14.590
202309 -2.806 129.860 -2.864
202312 -2.134 129.419 -2.186
202403 -2.110 131.776 -2.122
202406 -0.609 132.554 -0.609

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


T2 Biosystems  (FRA:3T2) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


T2 Biosystems Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


T2 Biosystems Business Description

Traded in Other Exchanges
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.

T2 Biosystems Headlines

No Headlines